Abstract:Neurodegenerative parkinsonian syndromes comprise a number of disorders that are characterized by similar clinical features but are separated on the basis of different pathologies, i.e., aggregates of α-synuclein or tau protein. Due to the overlap of signs and symptoms a precise differentiation is often difficult, especially early in the disease course. Enormous efforts have been taken to develop tau-selective PET imaging agents, but strong off-target binding to monoamine oxidase B (MAO-B) has been observed across first generation ligands. Nonetheless, astrogliosis-related MAO-B elevation is a common histopathological known feature of all parkinsonian syndromes and might be itself an interesting imaging target. Therefore, this study aimed to investigate the performance of [18F]-THK5351, a combined MAO-B and tau tracer for differential diagnosis of parkinsonian syndromes. [18F]-THK5351 PET was performed in 34 patients: six with Parkinson's disease (PD), nine with multiple system atrophy with predominant parkinsonism (MSA-P), six with MSA with predominant cerebellar ataxia (MSA-C), and 13 with progressive supranuclear palsy (PSP) Richardson's syndrome. Volume-of-interest-based quantification of standardized-uptake-values was conducted in different parkinsonian syndrome-related target regions. PET results were subjected to multinomial logistic regression to create a prediction model discriminating among groups. Furthermore, we correlated tracer uptake with clinical findings. Elevated [18F]-THK5351 uptake in midbrain and diencephalon differentiated PSP patients from PD and MSA-C. MSA-C patients were distinguishable by high tracer uptake in the pons and cerebellar deep white matter when compared to PSP and PD patients, whereas MSA-P patients tended to show higher tracer uptake in the lentiform nucleus. A multinomial logistic regression classified 33/34 patients into the correct clinical diagnosis group. Tracer uptake in the pons, cerebellar deep white matter, and striatum was closely associated with the presence of cerebellar and parkinsonian symptoms of MSA patients. The current study demonstrates that combined MAO-B and tau binding of THK5351 facilitates differential diagnosis of parkinsonian syndromes. Furthermore, our data indicate a correlation of MSA phenotype with [18F]-THK5351 uptake in certain brain regions, illustrating their relevance for the emergence of clinical symptoms and underlining the potential of THK5351 PET as a biomarker that correlates with pathological changes as well as with disease stage.

Tau-PET imaging in Parkinson's disease: a systematic review and meta-analysis

In Vivo F-18-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia

International Consensus on Clinical Use of Presynaptic Dopaminergic Positron Emission Tomography Imaging in Parkinsonism.

In Vivo <scp><sup>18</sup>F‐Florzolotau</scp> Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia

PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes

Imaging of dopamine transporters in Parkinson disease: a meta-analysis of <SUP>18</SUP>F/<SUP>123</SUP>I-FP-CIT studies

Imaging of dopamine transporters in Parkinson disease: a meta‐analysis of 18F/123I‐FP‐CIT studies

18F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies

Clinical Characteristics of Cognitive Impairment in Patients with Parkinson's Disease and Its Related Pattern in 18F‐FDG PET Imaging

18F-MK6240 PET imaging of tau protein in Alzheimer′s disease and cognitive correlation analysis

Dopaminergic and Metabolic Correlations with Cognitive Domains in Non-demented Parkinson's Disease.

Accumulation of Tau Protein, Metabolism and Perfusion—Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS)

Elevated Tau PET Signal Depends on Abnormal Amyloid Levels and Correlates with Cognitive Impairment in Elderly Persons without Dementia

Clinical Utility of 18F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy

Clinical Research of [18F]FDG Cerebral Metabolism and [11C]CFT Dopamine Transporter PET Imaging in Parkinson’s Disease

PET Imaging of Dopamine Transporter(DAT)in the Diagnosis of Parkinson's Disease

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.

Tau-PET abnormality as a biomarker for Alzheimer's disease staging and early detection: a topological perspective

Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study

Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer's Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers

Diagnostic performance of artificial intelligence-assisted PET imaging for Parkinson's disease: a systematic review and meta-analysis